13K shares changed hands in the last trading session. Trading volume was up 114.07% over the stocks average daily volume.
Traders are a little more bearish recently if you take note of the increase in short interest. The firm had a rise in short interest between September 29, 2017 and October 13, 2017 of 113.84%. Short shares grew from 6,736 to 14,404 over that period. With short interest at 14,404 and short average daily volume at 21,850, days to cover is 1.0 and the short interest percentage is 0.00% as of October 13.
These firms have modified their investment in OASM. Ubs Group Ag cut its ownership by shedding 3,686 shares a decrease of 50.3% as of 09/30/2017. Ubs Group Ag controls 3,641 shares valued at $4,000. The value of the position overall is down by 50.0%.
The company is now down by 1.00% percent from yesterday’s close. The company’s P/E ratio is N/A and the market cap is 525.69M. In the latest earnings report the EPS was $-1.28 with 172.88M shares presently outstanding.
Oasmia Pharmaceutical AB (publ) researches, develops, and manufactures drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company’s approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer. It is also developing Paclical for the treatment of metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin, for the treatment of breast cancer; Docecal, a patented formulation of cytostatic docetaxel, for the treatment of breast cancer; and OAS-19 to treat various cancers. Its product candidates for animal health comprise Paccal Vet-CA1, a formulation of paclitaxel, for the treatment of mastocytoma in dogs; and Doxophos Vet for the treatment of lymphoma in dogs. Oasmia Pharmaceutical AB was founded in 1990 and is based in Uppsala, Sweden..